San Francisco-based Presidio Pharmaceuticals, which is focused on developing therapies for chronic viral infections, has garnered $26 million in its second round. Panorama Capital led the round with Baker Brothers Investments, Bay City Capital, Ventures West Capital, Nexus Medical Partners and others participating.
"The proceeds of this financing will be used to advance two of our programs into human clinical studies, continue establishing alliances with outside partners, and expand our product portfolio through additional in-licensing transactions," said Dr. Omar K. Haffar, president and CEO of Presidio Pharmaceuticals.
- check out the release for more info
The top five VC deals of the first half of 2007. List